超滤治疗老年1型心肾综合征患者的疗效和安全性。

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiorenal Medicine Pub Date : 2025-01-01 Epub Date: 2025-05-19 DOI:10.1159/000546387
Lijuan Xu, Zhen Wang, Lei Sun, Bin Liu, Hongxiao Li
{"title":"超滤治疗老年1型心肾综合征患者的疗效和安全性。","authors":"Lijuan Xu, Zhen Wang, Lei Sun, Bin Liu, Hongxiao Li","doi":"10.1159/000546387","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Due to the typical exclusion of very elderly patients from clinical trials, the applicability of trial results to this population with heart failure remains uncertain. Limited data exist regarding the efficacy and safety of ultrafiltration in elderly patients with type 1 cardiorenal syndrome (CRS). Consequently, our study aimed to compare the efficacy and safety of ultrafiltration versus diuretics, providing evidence-based insights into the optimal management strategy for elderly patients with type 1 CRS.</p><p><strong>Methods: </strong>In this prospective pilot trial, patients aged over 70 years old with type I CRS were treated with either diuretics or ultrafiltration. All patients were followed for up to 180 days post-discharge. Efficacy outcomes encompassed both immediate measures (changes in weight and dyspnea score from baseline to 48 h posttreatment) and long-term stability indicators (length of hospital stay and heart failure-related medical visits within 180 days post-discharge). Safety outcomes were assessed in both groups, focusing on changes in systolic blood pressure, heart rate, serum creatinine, blood urea nitrogen, blood potassium, and sodium ion concentrations, bleeding or thromboembolic events, and major adverse cardiovascular events.</p><p><strong>Results: </strong>A total of 159 patients with type I CRS were enrolled, with 80 receiving diuretics and 79 undergoing ultrafiltration. The mean age was 82.1 ± 5.8 years. At 48 h, patients in the ultrafiltration group demonstrated significantly greater weight loss and improvements in dyspnea score compared to those in the diuretic group (p < 0.05). Furthermore, the ultrafiltration group had shorter hospital stays and fewer medical visits for heart failure within 180 days post-discharge (p < 0.05). Notably, there were no statistically significant differences in safety outcomes between the two groups, indicating comparable safety profiles.</p><p><strong>Conclusion: </strong>Ultrafiltration demonstrated superior efficacy with comparable safety profiles compared to diuretics. Therefore, ultrafiltration may be considered a preferred treatment option for elderly patients with type I CRS.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"430-438"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180765/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ultrafiltration in Elderly Patients with Type 1 Cardiorenal Syndrome: Efficacy and Safety Outcomes.\",\"authors\":\"Lijuan Xu, Zhen Wang, Lei Sun, Bin Liu, Hongxiao Li\",\"doi\":\"10.1159/000546387\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Due to the typical exclusion of very elderly patients from clinical trials, the applicability of trial results to this population with heart failure remains uncertain. Limited data exist regarding the efficacy and safety of ultrafiltration in elderly patients with type 1 cardiorenal syndrome (CRS). Consequently, our study aimed to compare the efficacy and safety of ultrafiltration versus diuretics, providing evidence-based insights into the optimal management strategy for elderly patients with type 1 CRS.</p><p><strong>Methods: </strong>In this prospective pilot trial, patients aged over 70 years old with type I CRS were treated with either diuretics or ultrafiltration. All patients were followed for up to 180 days post-discharge. Efficacy outcomes encompassed both immediate measures (changes in weight and dyspnea score from baseline to 48 h posttreatment) and long-term stability indicators (length of hospital stay and heart failure-related medical visits within 180 days post-discharge). Safety outcomes were assessed in both groups, focusing on changes in systolic blood pressure, heart rate, serum creatinine, blood urea nitrogen, blood potassium, and sodium ion concentrations, bleeding or thromboembolic events, and major adverse cardiovascular events.</p><p><strong>Results: </strong>A total of 159 patients with type I CRS were enrolled, with 80 receiving diuretics and 79 undergoing ultrafiltration. The mean age was 82.1 ± 5.8 years. At 48 h, patients in the ultrafiltration group demonstrated significantly greater weight loss and improvements in dyspnea score compared to those in the diuretic group (p < 0.05). Furthermore, the ultrafiltration group had shorter hospital stays and fewer medical visits for heart failure within 180 days post-discharge (p < 0.05). Notably, there were no statistically significant differences in safety outcomes between the two groups, indicating comparable safety profiles.</p><p><strong>Conclusion: </strong>Ultrafiltration demonstrated superior efficacy with comparable safety profiles compared to diuretics. Therefore, ultrafiltration may be considered a preferred treatment option for elderly patients with type I CRS.</p>\",\"PeriodicalId\":9584,\"journal\":{\"name\":\"Cardiorenal Medicine\",\"volume\":\" \",\"pages\":\"430-438\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180765/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiorenal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000546387\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546387","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

由于临床试验通常将高龄患者排除在外,因此试验结果对这一心力衰竭人群的适用性仍不确定。关于超滤治疗老年1型心肾综合征(CRS)患者的疗效和安全性的数据有限。因此,我们的研究旨在比较超滤与利尿剂的疗效和安全性,为老年1型CRS患者的最佳管理策略提供循证见解。方法在这项前瞻性先导试验中,年龄超过70岁的I型CRS患者接受利尿剂或超滤治疗。所有患者出院后随访180天。疗效结果包括即时测量(体重和呼吸困难评分从基线到治疗后48小时的变化)和长期稳定性指标(出院后180天内住院时间和心力衰竭相关的就诊次数)。对两组的安全性结果进行评估,重点关注收缩压、心率、血清肌酐、血尿素氮、血钾和钠离子浓度、出血或血栓栓塞事件以及主要不良心血管事件(MACE)的变化。结果共纳入159例I型CRS患者,其中80例接受利尿剂治疗,79例接受超滤治疗。平均年龄82.1±5.8岁。48小时时,超滤组患者的体重减轻程度和呼吸困难评分改善程度明显高于利尿剂组(P
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ultrafiltration in Elderly Patients with Type 1 Cardiorenal Syndrome: Efficacy and Safety Outcomes.

Introduction: Due to the typical exclusion of very elderly patients from clinical trials, the applicability of trial results to this population with heart failure remains uncertain. Limited data exist regarding the efficacy and safety of ultrafiltration in elderly patients with type 1 cardiorenal syndrome (CRS). Consequently, our study aimed to compare the efficacy and safety of ultrafiltration versus diuretics, providing evidence-based insights into the optimal management strategy for elderly patients with type 1 CRS.

Methods: In this prospective pilot trial, patients aged over 70 years old with type I CRS were treated with either diuretics or ultrafiltration. All patients were followed for up to 180 days post-discharge. Efficacy outcomes encompassed both immediate measures (changes in weight and dyspnea score from baseline to 48 h posttreatment) and long-term stability indicators (length of hospital stay and heart failure-related medical visits within 180 days post-discharge). Safety outcomes were assessed in both groups, focusing on changes in systolic blood pressure, heart rate, serum creatinine, blood urea nitrogen, blood potassium, and sodium ion concentrations, bleeding or thromboembolic events, and major adverse cardiovascular events.

Results: A total of 159 patients with type I CRS were enrolled, with 80 receiving diuretics and 79 undergoing ultrafiltration. The mean age was 82.1 ± 5.8 years. At 48 h, patients in the ultrafiltration group demonstrated significantly greater weight loss and improvements in dyspnea score compared to those in the diuretic group (p < 0.05). Furthermore, the ultrafiltration group had shorter hospital stays and fewer medical visits for heart failure within 180 days post-discharge (p < 0.05). Notably, there were no statistically significant differences in safety outcomes between the two groups, indicating comparable safety profiles.

Conclusion: Ultrafiltration demonstrated superior efficacy with comparable safety profiles compared to diuretics. Therefore, ultrafiltration may be considered a preferred treatment option for elderly patients with type I CRS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信